• STAT+: Alzheimer's scientists critique Cassava Sciences' study results - overblown, inappropriate, uninterpretable

    1 month ago - By STAT

    Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer's from Cassava Sciences.
    The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer's disease - a benefit that no other treatment for Alzheimer's has ever shown. Continue to STAT+ to read the full story...
    Read more ...